PHASE II ONCE-WEEKLY ALENDRONATE IN HIV-INFECTED SUBJECTS WITH DECREASED BONE D

II 期每周一次阿仑膦酸钠用于骨 D 减少的 HIV 感染者

• 批准号: 7625543
• 负责人: DAVID A WOHL
• 金额: $ 0.11万
• 依托单位: UNIV OF NORTH CAROLINA CHAPEL HILL
• 依托单位国家: 美国
• 财政年份: 2006
• 资助国家: 美国
• 起止时间: 2006-12-01 至 2007-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7625543
• 关键词: Alendronate; Calcium; Computer Retrieval of Information on Scientific Projects Database; Funding; Grant; HIV Infections; Institution; Personal Satisfaction; Persons; Phase; Purpose; Research; Research Personnel; Resources; Source; United States National Institutes of Health; Vitamin D; bone; bone loss

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The main purpose of this study is to find out if alendronate plus calcium and vitamin D is well tolerated, effective and safe to treat bone loss in persons with HIV infection compared to calcium and vitamin D alone.

该子项目是利用该技术的众多研究子项目之一 资源由 NIH/NCRR 资助的中心拨款提供。子项目及 研究者 (PI) 可能已从 NIH 的另一个来源获得主要资金， 因此可以在其他 CRISP 条目中表示。列出的机构是 对于中心来说，它不一定是研究者的机构。 本研究的主要目的是确定与单独使用钙和维生素 D 相比，阿仑膦酸钠加钙和维生素 D 治疗 HIV 感染者的骨质流失是否具有良好的耐受性、有效性和安全性。